SG11202111515TA - Ebv-specific immune cells - Google Patents

Ebv-specific immune cells

Info

Publication number
SG11202111515TA
SG11202111515TA SG11202111515TA SG11202111515TA SG11202111515TA SG 11202111515T A SG11202111515T A SG 11202111515TA SG 11202111515T A SG11202111515T A SG 11202111515TA SG 11202111515T A SG11202111515T A SG 11202111515TA SG 11202111515T A SG11202111515T A SG 11202111515TA
Authority
SG
Singapore
Prior art keywords
ebv
immune cells
specific immune
specific
cells
Prior art date
Application number
SG11202111515TA
Inventor
Cliona M Rooney
Sandhya Sharma
Original Assignee
Baylor College Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baylor College Medicine filed Critical Baylor College Medicine
Publication of SG11202111515TA publication Critical patent/SG11202111515TA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A61K39/464429—Molecules with a "CD" designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/464838—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/03—Herpetoviridae, e.g. pseudorabies virus
    • C07K14/05—Epstein-Barr virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/51—B7 molecules, e.g. CD80, CD86, CD28 (ligand), CD152 (ligand)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998—Proteins not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
    • C12N2502/1114—T cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16211—Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
    • C12N2710/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16211—Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
    • C12N2710/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
SG11202111515TA 2019-04-18 2020-04-09 Ebv-specific immune cells SG11202111515TA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16/388,776 US10772914B1 (en) 2019-04-18 2019-04-18 EBV-specific immune cells
PCT/US2020/027456 WO2020214479A1 (en) 2019-04-18 2020-04-09 Ebv-specific immune cells

Publications (1)

Publication Number Publication Date
SG11202111515TA true SG11202111515TA (en) 2021-11-29

Family

ID=72425595

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202111515TA SG11202111515TA (en) 2019-04-18 2020-04-09 Ebv-specific immune cells

Country Status (10)

Country Link
US (2) US10772914B1 (en)
EP (1) EP3955958A4 (en)
JP (1) JP2022529687A (en)
KR (1) KR20210153685A (en)
CN (1) CN113939312A (en)
AU (1) AU2020257876A1 (en)
CA (1) CA3137070A1 (en)
SG (1) SG11202111515TA (en)
TW (1) TW202104245A (en)
WO (1) WO2020214479A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021221927A1 (en) 2020-04-27 2021-11-04 Parsons Corporation Narrowband iq signal obfuscation
EP4330379A2 (en) * 2021-04-27 2024-03-06 Baylor College of Medicine Virus-specific immune cells expressing chimeric antigen receptors
WO2023060179A1 (en) * 2021-10-08 2023-04-13 Baylor College Of Medicine Generation of t cell lines with specificity against one or more neoantigens
WO2023198744A1 (en) 2022-04-13 2023-10-19 Tessa Therapeutics Ltd. Therapeutic t cell product

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5641628A (en) 1989-11-13 1997-06-24 Children's Medical Center Corporation Non-invasive method for isolation and detection of fetal DNA
US6821778B1 (en) 1993-12-01 2004-11-23 The Board Of Trustees Of Leland Stanford Junior University Methods for using dendritic cells to activate gamma/delta-T cell receptor-positive T cells
US6300090B1 (en) 1994-07-29 2001-10-09 The Rockefeller University Methods of use of viral vectors to deliver antigen to dendritic cells
ES2170195T3 (en) * 1995-06-06 2002-08-01 Organon Teknika Bv PEPTIDES OF THE EPSTEIN-BARR VIRUS AND ANTIBODIES AGAINST THESE PEPTIDES.
ATE428769T1 (en) 1997-10-27 2009-05-15 Univ Rockefeller METHOD AND COMPOSITION FOR PRODUCING MATURE DENDRITIC CELLS
JP2003519473A (en) 1999-11-24 2003-06-24 アーネスト ジー． ホープ Anti-angiogenic cellular substances for cancer treatment
US20040022761A1 (en) 2001-05-11 2004-02-05 Banchereau Jacques F Compositions and methods for producing antigen-presenting cells
DK1429597T3 (en) 2001-09-28 2006-05-01 Heinrich-Guenter Schumacher Cutting knife with one of the rails composed of a knife rail
IL158140A0 (en) 2003-09-25 2004-03-28 Hadasit Med Res Service Multiepitope polypeptides for cancer immunotherapy
CA2542116C (en) 2003-10-08 2015-01-27 Wilson Wolf Manufacturing Corporation Cell culture methods and devices utilizing gas permeable materials
US7785875B2 (en) 2004-07-03 2010-08-31 Mogam Biotechnology Research Institute Polynucleotide encoding HCV epitopes which can bind to various HLA supertypes, immunogenic composition comprising same and method of inducing an HCV-specific immune response using same
US20060045883A1 (en) 2004-08-26 2006-03-02 Jeffrey Molldrem Anti-cancer vaccines
JP4731867B2 (en) 2004-10-01 2011-07-27 国立大学法人三重大学 Method for inducing CD8 positive cytotoxic T lymphocytes
JP4824389B2 (en) 2005-10-28 2011-11-30 株式会社医学生物学研究所 Cytotoxic T cell epitope peptide that specifically attacks Epstein-Barr virus infected cells and uses thereof
JP5492418B2 (en) * 2005-11-18 2014-05-14 ザ オハイオ ステート ユニバーシティー リサーチ ファウンデーション Viral gene products and vaccination methods for preventing virus-related diseases
US20070243549A1 (en) 2006-04-12 2007-10-18 Biocept, Inc. Enrichment of circulating fetal dna
CA2671967A1 (en) 2006-12-07 2008-06-19 Wilson Wolf Manufacturing Corporation Highly efficient devices and methods for culturing cells
WO2009053109A1 (en) 2007-10-24 2009-04-30 Anne Letsch Antigen-specific t-cell preparations from bone marrow
DK2470644T3 (en) * 2009-08-24 2017-01-16 Baylor College Medicine GENERATION OF CTL LINES WITH SPECIFICITY AGAINST MORE TUMOR ANTIGEN OR MORE
US20130115617A1 (en) * 2009-12-08 2013-05-09 John R. Wilson Methods of cell culture for adoptive cell therapy
GB201121308D0 (en) 2011-12-12 2012-01-25 Cell Medica Ltd Process
HRP20221303T1 (en) 2012-02-09 2022-12-23 Baylor College Of Medicine Pepmixes to generate multiviral ctls with broad specificity
WO2016073595A1 (en) 2014-11-05 2016-05-12 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services T cells and dendritic cells for polyomavirus therapy
AU2017326173B2 (en) * 2016-09-16 2022-08-18 Baylor College Of Medicine Platform for activation and expansion of virus-specific T-cells

Also Published As

Publication number Publication date
AU2020257876A1 (en) 2021-12-02
KR20210153685A (en) 2021-12-17
TW202104245A (en) 2021-02-01
EP3955958A4 (en) 2023-01-25
US20220401478A1 (en) 2022-12-22
US10772914B1 (en) 2020-09-15
EP3955958A1 (en) 2022-02-23
CN113939312A (en) 2022-01-14
WO2020214479A1 (en) 2020-10-22
JP2022529687A (en) 2022-06-23
CA3137070A1 (en) 2020-10-22

Similar Documents

Publication Publication Date Title
CA196170S (en) Charger
SG11202111515TA (en) Ebv-specific immune cells
IL288221A (en) Safe immuno-stealth cells
IL299911A (en) Improving immune cell function
GB201819540D0 (en) T cell modification
CA189861S (en) Charger
GB201904971D0 (en) Cell
CA206608S (en) Charger
GB201906202D0 (en) Cell
SG11202108740UA (en) Engineered immune cells
GB201914611D0 (en) Engineered immune cell
EP4048783C0 (en) Modified cell
IL269146A (en) Infected cell cultures
IL304559A (en) Self-polarizing immune cells
GB201906687D0 (en) Solar
GB201906043D0 (en) Solar
GB201905827D0 (en) Solar
CA201490S (en) Charger
CA189125S (en) Charger
ZA202007272B (en) Energy arrangement
GB201919017D0 (en) Cell
GB201918906D0 (en) Cell
GB201918908D0 (en) Cell
EP3790842C0 (en) Solar receiver-reactor
GB2577249B (en) Charger arrangement